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Abstract
Background: Recent studies have demonstrated an inflammatory response associated with the pathophysiology of
cerebral ischemia. The beneficial effects of anti-inflammatory drugs in cerebral ischemia have been documented.
When screening natural compounds for drug candidates in this category, we isolated 6-O-acetyl shanzhiside
methyl ester (ND02), an iridoid glucoside compound, from the leaves of Lamiophlomis rotata (Benth.) Kudo. The
objectives of this study were to determine the effects of ND02 on a cultured neuronal cell line, SH-SY5Y, in vitro,
and on experimental ischemic stroke in vivo.
Methods: For TNF-a-stimulated SH-SY5Y cell line experiments in vitro, SH-SY5Y cells were pre-incubated with
ND02 (20 μMo r4 0μM) for 30 min and then incubated with TNF-a (20 ng/ml) for 15 min. For in vivo experiments,
rats were subjected to middle cerebral artery occlusion (MCAO) for 1 h followed by reperfusion for 23 h.
Results: ND02 treatment of SH-SY5Y cell lines blocked TNF-a-induced nuclear factor-B (NF-B) and IB-a
phosphorylation and increased Akt phosphorylation. LY294002 blocked TNF-a-induced phosphorylation of Akt and
reduced the phosphorylation of both IB-a and NF-B. At doses higher than 10 mg/kg, ND02 had a significant
neuroprotective effect in rats with cerebral ischemia and reperfusion (I/R). ND02 (25 mg/kg) demonstrated
significant neuroprotective activity even after delayed administration 1 h, 3 h and 5 h after I/R. ND02, 25 mg/kg,
attenuated histopathological damage, decreased cerebral Evans blue extravasation, inhibited NF-B activation, and
enhanced Akt phosphorylation.
Conclusion: These data show that ND02 protects brain against I/R injury with a favorable therapeutic time-window
by alleviating cerebral I/R injury and attenuating blood-brain barrier (BBB) breakdown, and that these protective
effects may be due to blocking of neuronal inflammatory cascades through an Akt-dependent NF-B signaling
pathway.
Background
Ischemic brain injury resulting from diseases such as
stroke is the third leading cause of death in the United
States and a leading cause of lethality and disability in
European countries. Although much is now known
about the molecular consequences of ischemic brain
injury, few therapeutic treatments have proven success-
ful in clinical trials [1]. The inflammatory response to
brain injury plays a vital role in the pathogenesis of
stroke [2,3]. Previous studies have demonstrated that
agents with anti-inflammatory action have therapeutic
potential for experimental stroke [4].
There is ample evidence indicating that NF-Bi s
activated in cerebral ischemia and reperfusion (I/R),
especially in neurons [5-8]. This suggests that inhibition
of NF-B may represent a treatment strategy in
ischemic stroke. Previous studies have shown that
aspirin and several structurally diverse compounds
provide neuroprotection during cerebral ischemia via
inhibition of NF-B activation [9-13].
Akt, a serine/threonine protein kinase, plays a critical
role in controlling the balance between apoptosis and
cell survival in response to extra- and intracellular
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mia involve phosphoinositide 3-kinase (PI3K)/Akt
[14-17]. Akt signaling exerts its neuroprotective role in
cerebral ischemia animal models [18-20] via blocking of
NF-B activation, through IkB phosphorylation and
degradation [21].
6-O-acetyl shanzhiside methyl ester (ND02, Figure 1)
is an iridoid glucoside compound isolated from the
leaves of Lamiophlomis rotata (Benth.) Kudo., which is a
Chinese folk medicinal plant in Xi-zang (Tibet). For
thousands of years, Lamiophlomis rotata has been used
in pain alleviation, detumescence, hemostasis, marrow
reinforcement and promotion of blood circulation to
remove stasis [22]. There are many iridoid glucoside
compounds in the leaves of Lamiophlomis rotata
(Benth.) Kudo, however, ND02 and 8-O-acetyl shanzhi-
side methyl ester are the main components. Previous
studies have shown that 8-O-acetyl shanzhiside methyl
ester attenuates apoptosis and ameliorates mitochondrial
energy metabolism in rat cortical neurons exposed to
oxygen-glucose deprivation [23]. ND02 is also found in
the root of Phlomis medicinalis Die [24]. The objective
of this study was to determine the effects of ND02 on
the inflammatory response of neurons and to explore
whether ND02 can protect brain against injury in a rat
model of I/R.
Methods
Materials
ND02 (Molecular Formula: C19H28O12;C A SN O . :
110186-13-5; Chemical name: methyl(1 S,4aS,5R,7
S,7aS)-5-acetyloxy-7-hydroxy-7-methyl-1-[(2 S,3R,4 S,5
S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-
4a,5,6,7a-tetrahydro-1H-cyclopenta [c] pyran-4-carboxy-
late, purity > 98.5%) was provided by the State Key
Laboratory of Long-acting Extended-Release and Target-
ing Drug Delivery Systems (Luye Pharma Group Ltd.),
Y a n t a i ,P .R .C h i n a ) .I t se x t r a c t i o na n di s o l a t i o nw e r e
carried out according to a previously described proce-
dure [24].
Cell culture
Human neuroblastoma (SH-SY5Y) cells were obtained
from the Shanghai cell bank of the Chinese Academy of
Sciences. SH-SY5Y cells were cultured and maintained
in F12 + DMEM (1,1, v/v) media, supplemented with
10% FBS and 1% penicillin/streptomycin. Cells were
kept at 37°C in a humidified 5% CO2/95% air incubator.
For TNF-a-stimulated SH-SY5Y cell line experiments in
vitro, SH-SY5Y cells (5 × 10
6) were pre-incubated with
PI3 kinase inhibitor, LY294002 (30 μM, Calbiochem, La
Jolla, CA) or ND02 (20 μMo r4 0μM) for 30 min and
then incubated with TNF-a (20 ng/ml) for 15 min.
Western blot analysis
Cells were cultured for 24 h, then washed twice with ice
cold PBS on ice and lysed in NP40 lysis buffer (Bio-
source, Camarillo, CA, USA) (50 mM Tris, pH 7.4, 250
mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO4,
1% NP-40 and 0.02% NaN3) supplemented with 1 mM
PMSF and 1 × protease inhibitor cocktail (Sigma, Saint
Louis, MO, USA). Equal amounts of cell protein (50 μg)
were separated by SDS-PAGE and analyzed by western
blot using specific antibodies to phospho-IB-a,p h o s -
pho-NF-B, phospho-Akt and b-actin (as a loading con-
trol). The antibodies were all purchased from Beijing
Biosynthesis Biotechnology Company (Beijing, P. R.
China). Optical densities of the bands were scanned and
quantified with a Gel Doc 2000 (Bio-Rad Laboratories
(UK) Ltd). Data were normalized against those of the
corresponding b-actin bands. Results were expressed as
fold increase over control.
Animals
Adult male Sprague-Dawley rats were obtained from
Shandong Luye-Pharmaceutical Company (Yantai, P. R.
China). All animals were housed individually at 22 ±
2°C and a relative humidity of 50 ± 10% and with a
12-h light/dark cycle, and had free access to chow and
water. The experimental procedures were approved by
the Binzhou Medical University’s Administrative Panel
on Laboratory Animal Care.
Rat cerebral ischemia study protocol
T h eb o d yw e i g h to ft h er a t sa tt h et i m eo ft h ee x p e r i -
ments was 280-310 g. After 1 week of acclimatization,
Figure 1 The chemical structure of ND02.
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i.p.). Rectal temperatures were recorded and maintained
at 37°C during surgery with a heating-pad. The middle
cerebral artery occlusion (MCAO) operation was carried
out according to a previous procedure with minor modi-
fications [25]. The left common carotid artery was
occluded, and the branches of the external carotid artery
were dissected and divided. The internal carotid artery
was followed rostrally and a 4-0 filament (Beijing
Shadong Biology Company, P. R. China; the diameter of
the filament is 0.25, but the diameter of the tip is
0.34 mm to create a globular stopper) was introduced
into the internal carotid artery and advanced until resis-
tance was felt. The filament was removed after 1 h. The
rats were kept under 24°C-25°C conditions for the first
24 h after surgery.
For dose-response studies, 105 rats were randomly
divided into 7 groups of 15 rats each. ND02 at doses of
1.6, 4, 10, 25 and 62.5 mg/kg was administered as a
bolus injection into the tail vein 30 min after reperfu-
sion. (The ND02 was dissolved in sterile saline to make
stock solutions, and dilutions were then prepared for
different final concentrations.) Sham or vehicle-treated
rats were injected with saline. Rectal temperature was
determined once every 3 h for a total of 8 times. Neuro-
logical deficits were determined 24 h after ischemia,
followed by brain infarct volume examinations.
For therapeutic time-window studies, 90 rats were
randomly divided into 6 groups. ND02 at a dose of 25
mg/kg was administered as a bolus injection into the
tail vein at 1 h, 3 h, 5 h and 7 h after reperfusion. Vehi-
cle-treated rats were injected with saline. Neurological
deficits were determined 24 h after ischemia, followed
by brain infarct examinations.
For anti-inflammatory mechanism studies, 90 rats
were randomly divided into three groups, and each of
these into three subgroups of 10 rats each. ND02 at a
dose of 25 mg/kg was administered as a bolus injection
into the tail vein 30 min after reperfusion. Sham or
vehicle-treated rats were injected with saline. The three
groups were evaluated for Evans blue extravasation, by
western blots, and for histopathological damage by
NeuN staining 24 h after ischemia.
For long-term studies, 40 rats were randomly divided
into two groups of 20 rats each: an ND02-treated
(25 mg/kg) group and a vehicle-treated group. ND02
was administered as a bolus injection into the tail vein
30 min after reperfusion and once every 24 h for 7 con-
secutive days. Vehicle-treated rats were injected with
saline. Neurological deficits were determined on the 3rd,
7th and 14th days after I/R. Fourteen days after I/R,
8 rats in each group were randomly selected for brain
infarct examination.
Evaluation of neurological deficits
Neurological deficits were evaluated using a modified
six-point scoring method [26] by an investigator who
was blinded to the experimental treatment groups. The
scale is 0: no neurological deficit (normal); 1: failure to
extend the left forepaw fully (mild); 2: circling to the left
(moderate); 3: falling to the left (severe); 4: no sponta-
neous walking with a depressed level of consciousness
(very severe) and 5: dead.
Evaluation of infarct volume and brain water content
Rats were decapitated 23 h after reperfusion, and their
brains quickly removed. Total wet weight of the brain was
measured accurately, and each brain was then sliced into
five coronal sections of 2-mm thickness each and stained
with a 2% solution of tetrazolium chloride (TTC, Sigma)
in saline at 37°C for 20 min, and then photographed. The
images were digitized and used to calculate infarct volume
with a Compix system computer (C imaging 1280
system),. Afterwards, brain water content was determined
as an indicator of cerebral edema using a wet/dry method
as previously described [27].
Evaluation of blood-brain barrier (BBB) leakage with
Evans blue extravasation
Determination of Evans blue extravasation was based on
a previous method [28] with minor modifications. After
reperfusion, 0.1 ml of 4% Evans blue (Urchem, Shanghai,
P. R. China) in 0.9% saline was intravenously adminis-
tered. Twenty-three hours after I/R, each rat was per-
fused with 20 ml 10 U/ml heparinized saline to wash
out blood. The brain was then isolated, weighed and
homogenized in 50% solution of trichloroacetic acid.
After centrifugation at 400 × g for 20 min, the superna-
tant was spectrophotometrically measured at 610 nm.
Cerebral Evans blue was quantified as micrograms of
dye per gram of wet weight.
Western blots analysis in I/R rats
For western blot analysis of collected brain tissues, the
tissues were defrosted and immersed in ice-cold lysis
b u f f e r( 5 0m MT r i s - H C l ,1m ME D T A ,1m ME G T A ,
0.5 mM Na3VO4, 0.1% 2-mercaptoethanol, 1% Triton
X-100, 50 mM NaF, 5 mM sodium pyrophosphate,
10 mM sodium b-glyceropyrophosphate, 0.1 mM
phenylmethanesulfonyl fluoride, and protease inhibitor
mixture) for 10 min. Supernatant was collected after a
shake in 1% p-nitorphenyl phosphate for 10 s, and
centrifugation at 4°C and 12,000 × g for 30 s. Equal
amounts of protein were separated by SDS-PAGE and
analyzed by western blot using antibodies (Beijing
Biosynthesis Biotechnology Company, P. R. China)
to phospho-IB-a,p h o s p h o - N F - B, phospho-Akt and
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scanned and quantified with a Gel Doc 2000 (Bio-Rad).
The data were normalized against those of the corre-
sponding b-actin bands. Results were expressed as fold
increase over sham animals.
NeuN staining
NeuN-immunolabeling was carried out by incubating
free floating coronal sections (5 μm) with anti-NeuN
antiserum and 3,3-diaminobenzidine tetra hydrochloride
(DAB). First, coronal sections were washed twice for 20
min in TBS buffer (0.15 M NaCl; 0.1 M Tris-HCl, pH
7.5) at room temperature. This was followed by a 30-
min incubation in TBS-BSA [TBS containing 1% (w/v)
BSA and 3% normal goat serum (NGS)] at room
temperature to block nonspecific antibody binding. The
sections were then incubated overnight with 1:500 anti-
NeuN antiserum (Beijing Biosynthesis Biotechnology
Company, P.R. China) diluted in 1% NGS in TBS at 4°C.
After three 10-min washings with 1% NGS in TBS, the
sections were incubated with 1:250 biotinylated anti-
mouse IgG (Secondary antibody, Fuzhong Maixin Bio-
technology Company, P.R. China) for 1 h in 1% NGS in
TBS at room temperature. NeuN-immunostaining was
visualized using the streptomycete antibiotin-peroxidase
solution and DAB.
To evaluate neurological damage after cerebral I/R 24 h,
the left hemisphere of each brain was cut coronally into
three blocks from the level of the optic chiasm and the
infundibular stem of the hypophysisi. The middle block
was further cut into three sub-blocks. The middle sub-
block (0.1 × 0.1 cm) was embedded in paraffin and immu-
noreacted for NeuN. NeuN-immunopositive cells were
counted at 400 × magnification in three selected fields in
the central zone of the middle sub-block (0.1 × 0.1 cm).
A final value for number of NeuN-immunopositive cells
was calculated by averaging the counts of three fields.
To evaluate brain infarct volume after cerebral I/R of
14 days duration, rats were killed 14 days after I/R. The
brains were fixed by transcardial perfusion with saline,
followed by perfusion and immersion in 4% paraformal-
dehyde before being embedded in paraffin. Seven coronal
sections of tissue were processed and immunoreacted for
NeuN for calculation of volume of cerebral infarction
[29]. Indirect infarct area was calculated by subtracting
the intact area of the ipsilateral hemisphere from the area
of the contralateral hemisphere [29]. Infarct volume is
presented as a volume percentage of the lesion compared
with the contralateral hemisphere.
Statistical analysis
Neurological deficit scores between groups were ana-
lyzed using a nonparametric test. Quantitative data from
the experiments are expressed as mean ± SD. Statistical
significance was determined by one-way analysis of var-
iance (ANOVA) followed by Dunnett’s test. In all cases,
differences were considered significant if P < 0.05.
Results
ND02 blocks NF-B activation through Akt signaling
pathway
We compared the effect of ND02 on TNF-a-induced
( 2 0n g / m lf o r1 5m i n )a c t i v a t i o no fI B-a,N F - Ba n d
Akt in the SH-SY5Y cell line to that of a selective PI3K
inhibitor, LY294002. The results (Figure 2) show that
pretreatment of SH-SY5Y cells with LY294002 (30 μM)
for 30 min blocked TNF-a-induced phosphorylation of
Akt and reduced the phosphorylation of both IB-a and
NF-B. ND02, 20 μMa n d4 0μMt r e a t m e n t so fS H -
SY5Y cells, blocked TNF-a-induced IB-a and NF-B
phosphorylation, while increasing Akt phosphorylation
(Figure 2).
ND02 reduces brain infarct volume, brain water content
and neurological deficit scores in cerebral I/R rats
Cerebral I/R leads to severe behavioral disturbance and
histological changes in rats. Compared with sham-oper-
ated animals, neurological deficit, cerebral infarct
volume and cerebral edema were significant higher in
cerebral I/R rats.
The results of dose-response studies are shown in
Table 1. ND02 at doses of 10, 25 and 62.5 mg/kg, admi-
nistered intravenously 30 min after I/R, decreased neu-
rological deficit scores, reduced cerebral infarct volume
and brain water content in a dose dependent manner.
The results of therapeutic time-window studies are
shown in Table 2. ND02 at a dose of 25 mg/kg signifi-
cantly decreased neurological deficit scores, reduced cer-
ebral infarct volume and brain water content even with
delayed administration 1 h, 3 h and 5 h after I/R.
Obviously, earlier administration of this compound
brings more therapeutic benefit.
The results of long-term studies are shown in Table 3.
ND02 at an i.v. dose of 25 mg/kg 30 min after I/R sig-
nificantly decreased neurological deficit scores and
reduced cerebral infarction 14 days after I/R. The results
of NeuN immunolabeling indicated that this is likely
due to a significantly increased number of surviving
neurons 24 h and 14 days after cerebral I/R, as shown
in Figure 3A and Figure 3B. Thus, it is clear that early
treatment with ND02 provides long-term benefits for
neuronal functional recovery after cerebral I/R.
ND02 attenuates the increase of cerebral Evans blue
extravasation in I/R rats
Evans blue extravasation was used to assess of BBB
breakdown after cerebral ischemia. The results of Evans
blue extravasation clearly shows that this pathological
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by ND02 treatment, as shown in Table 4.
ND02 attenuates the decrease of NeuN-immunopositive
neurons
The number of NeuN-immunopositive neuron is a reli-
able indicator of cerebral injury. After 24 h of IR, the
number of NeuN-immunopositive neuron was decreased
in cerebral cortex, as shown in Figure 3B. ND02
treatment (25 mg/kg) alleviated this damage to neurons
24 h and 14 days after cerebral I/R.
ND02 attenuates cerebral NF-B activation in cerebral
I/R rats
To investigate the molecular mechanism of the ND02
protective effects, NF-B activation and phosphorylated
Akt were examined. Phosphorylation of IB-a and
NF-B occurred in rats after cerebral I/R, but were not
Figure 2 ND02 inhibits TNF-a-induced phosphorylation of NF-B and IB-a through an Akt signaling pathway. SH-SY5Y cells were pre-
incubated with PI3 kinase inhibitor, ly294002 (30 μM) or ND02 (20 μ Mo r4 0μ M) for 30 min and then incubated with TNF-a (20 ng/ml) for
15 min. Phospho-Akt, Phospho-IB-a and Phospho-NF-B expression were analyzed by western blotting. Results are expressed as fold increase
over control, n = 5.
aP < 0.05,
bP < 0.01 vs. TNF-a-induced group.
cP < 0.01 vs. control group. Significance was determined by one-way analysis
of ANOVA followed by Dunnett’s test.
Table 1 Effects of ND02 on survival, neurological scores, infarct volume, and brain water content in ischemia-
reperfused rats: a dose-response study
Group Survival (# rats) Neurological scores (median/range) Infarct volume (%) Brain water content (%)
Sham 15/15 —— 76.8 ± 0.5
Vehicle-treated 9/15 4/2 27.4 ± 6.3 78.8 ± 0.4
ND02 1.6 mg/kg 9/15 4/3 24.8 ± 4.2 78.6 ± 0.4
ND02 4 mg/kg 10/15 4/3 23.3 ± 4.8 78.4 ± 0.5
ND02 10 mg/kg 10/15 3/3* 19.7 ± 6.2* 78.2 ± 0.7*
ND02 25 mg/kg 11/15 3/4** 17.4 ± 4.8** 77.9 ± 0.5**
ND02 62.5 mg/kg 12/15 2/4** 12.8 ± 3.5** 77.8 ± 0.5**
Data are means ± SD, with n = 15 for each group. ND02, at doses ranging from 1.6 to 62.5 mg/kg, was administered intravenously 30 min after cerebral I/R.
#P < 0.01 vs. sham group; *P < 0.05, **P < 0.01 vs vehicle-treated group. Cerebral infarct volume and brain water content between groups were compared using
one-way ANOVA followed by Dunnett’s test. Neurological scores between groups were compared using a nonparametric test.
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treatment reduced phosphorylated IB-a and NF-B
levels, while increasing phosphorylated Akt levels. These
data indicate that ND02 inhibits NF-B activation
through Akt signaling pathway in cerebral I/R rats.
Discussion
In the present study, we observed significant improve-
ment of brain injury after treatment with ND02 in rats
subjected to cerebral I/R challenge in an I/R model.
Stoke triggers an inflammatory reaction that progresses
for hours after the onset of a stroke, and this inflamma-
tion plays a central role in the pathogenesis of neuronal
injury in ischemic stroke. Inflammation is thought to
contribute to the genesis of secondary damage as the
consequence of activation of resident perivascular and
parenchymal macrophages, and infiltration of peripheral
inflammatory cells [30]. This postischemic inflammation
occurs a few hours to days after a primary ischemic
event, and is associated with delayed injury [31]. In par-
ticular, inflammatory reactions contribute to the late
stages of ischemic injury and to worsened neurological
outcome through multiple mechanisms [32]. The pre-
sent study indicates that ND02 has anti-inflammatory
effects (Table 4, Figure 2 and Figure 4). Treatment with
ND02 especially provided long-term benefits for neuro-
nal functional recovery after cerebral I/R (Table 3). This
suggests that the neuroprotective effects of ND01 may
be to block the inflammatory response. In addition,
determinations of ND02 in brain tissue by HPLC after
i.v. administration of ND02 25 mg/kg indicate that
ND02 can penetrate the blood-brain barrier.
Infarction, the main pathophysiological outcome of
cerebral ischemia, entails neuronal degeneration and
necrosis [33]. Our results (Table 1) reveal that ND02
treatment produces significant reduction in cerebral
infarct volume in cerebral I/R model rats. Neuronal
degeneration and necrosis have been found to be corre-
lated to deficits in behavioral disturbance, and the pre-
sent study shows that neurological scores are improved
by treatment with ND02 (Table 1). NeuN is a resoluble
nuclear protein with a molecular weight of 46 kDa, and
is a widely used marker for mature neurons. NeuN is
expressed in the nucleus and cell bodies of most neu-
rons but not in glial cells, including oligodendrocytes,
astrocytes, and microglial cells [34,35]. Immunoreactivity
for NeuN has been reported to decrease dramatically
following CNS injury [36-39], and NeuN is a sensitive
marker for injured neurons early after ischemic chal-
lenge [40]. Thus the number of NeuN-immunopositive
neuron in ischemic cerebral cortex is a reliable indicator
of cerebral injury. Our data (Figure 3) demonstrate that
i.v. ND02, 25 mg/kg, attenuates the decrease in NeuN-
immunopositive neurons in ischemic cerebral cortex
Table 2 Effects of ND02 on survival, neurological scores, infarct volume, and brain water content in ischemia-
reperfused rats: a therapeutic time-window study
Group Survival (# rats) Neurological scores (median/range) Infacrt volume (%) Brain water content (%)
Sham 15/15 —— 76.7 ± 0.5
Vehicle-treated 10/15 4/2 26.1 ± 4.5 78.9 ± 0.4
1 h 13/15 2/3** 15.8 ± 3.9** 77.9 ± 0.6**
3 h 12/15 3/4* 18.6 ± 5.1** 78.1 ± 0.4**
ND02 25 5 h 11/15 3/3* 21.8 ± 4.1* 78.4 ± 0.5*
7 h 10/15 3/3 22.9 ± 6.6 78.6 ± 0.4
Data are means ± SD, with n = 15 for each group. ND02 was administered at a dose of 25 mg/kg at 1 h, 3 h, 5 h and 7 h after cerebral I/R. Data are means ±
SD.
#P < 0.01 vs. sham group; *P < 0.05, **P < 0.01 vs vehicle-treated group. Cerebral infarct volumes of different groups were compared using one-way ANOVA
followed by Dunnett’s test. Neurological deficit scores between groups were compared using a nonparametric test.
Table 3 Effects of ND02 on survival, neurological scores, infarct volume, and brain water content in ischemia-
reperfused rats: a long-term study
Group Time (days) Survival (# rats) Neurological scores (median/range) Infarct volume (%)
3 15/20 4/3
Vehicle-treated 7 14/20 3/4
14 13/20 3/4 27.6 ± 5.8
3 17/20 2/4**
ND02 25 7 16/20 2/4*
14 16/20 2/4* 13.9 ± 4.7**
ND02 was administered at a dose of 25 mg/kg as a single intravenous bolus injection 30 min after cerebral I/R. This led to significantly decreased neurological
deficit scores and reduced cerebral infarct volume within 14 days after I/R. Data are means ± SD, each group is 20 rats. *P < 0.05, **P < 0.01 vs vehicle-treated
group. Cerebral infarct volumes of different groups were compared using one-way ANOVA followed by Dunnett’s test. Neurological deficit scores between
groups were compared using a nonparametric test.
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potentially beneficial in treatment of cerebral ischemia.
BBB tight junction permeability is altered in ischemic
stroke [41]. BBB breakdown occurs in the early phase
(within 24 h) of cerebral ischemia [42,43]. This break-
down of BBB leads to massive brain edema, which is the
main cause of death in acute stroke [44]. The brain
becomes devoid of protection from toxic substances car-
ried by circulating blood upon BBB disruption. Attenu-
ating BBB disruption provides a strong neuroprotective
effect and ameliorates secondary injury [45]. Cerebral
Evans blue extravasation is a commonly used biomarker
of BBB permeability. Our data (Table 4) demonstrate
that ND02, 25 mg/kg i.v., reduces cerebral Evans blue
extravasation after cerebral I/R. These results indicate
that ND02 improves cerebral I/R injury by attenuating
BBB breakdown.
A recent update of the Stroke Therapy Academic
Industry Roundtable Preclinical Recommendations [46]
lists three potential reasons for failures in translating
efficacious preclinical findings into successful clinical
trial outcomes: (i) a very tight dose range with sa teep
dose-response curve; (ii) inadequate investigation of
therapeutic time-windows for initiation of treatment and
(iii) differences in observation period between animal
models and clinical trials. Consequently, we investigated
the dose-response (Table 1), therapeutic time window
(Table 2) and long-term efficacy (Table 3) of ND02 in
cerebral I/R rats. Our data demonstrate that ND02
exerts potent and long-term neuroprotective effects with
an appropriate dose-response curve and a favorable
therapeutic time-window in the model of cerebral I/R.
It is well established that NF-B activation is asso-
ciated with phosphorylation of IB-a and NF-B
[47,48]. Animals exempted from NF-B activation or
Figure 3 Effect of ND02 on neurological damage 24 h and 14 days after cerebral ischemia-reperfusion (I/R). Figure. 3A: Effect of ND02 on
cerebral pathological damage after cerebral I/R. Sections were stained with NeuN after fixation. A1: Sham group; A2: Vehicle-treated group (24 h);
A3: ND02 25 mg/kg group; A4: Vehicle-treated group (14th day); A5: ND02, 25 mg/kg, group (14th day). Figure 3B: Effect of ND02 on the NeuN-
immunopositive neurons after cerebral I/R. Results were averaged and are expressed as number of NeuN-immunopositive neurons per section.
Data are means ± SD, n = 5.
aP < 0.01 vs vehicle-treated group. Significance was determined by one-way ANOVA followed by Dunnett’s test.
Table 4 Effect of ND02 on cerebral Evans blue
extravasation in ischemia-reperfused rats
Group Dose
(mg/kg)
Evans blue extravasation
(μg/g wet weight)
Sham — 0.47 ± 0.11
Vehicle-treated — 3.31 ± 0.62#
ND02 25 1.76 ± 0.39**
Data are means ± SD, with n = 10 for each group.
#P < 0.01 vs. sham group;
*P < 0.05, **P < 0.01 vs vehicle-treated animals. Significance was determined
by one-way ANOVA followed by Dunnett’st e s t .
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[49]. Akt phosphorylates IB kinase, and activated IB-
a, in turn, causes activation and nuclear translocation of
NF-B-dependent prosurvival genes [50]. A curb on the
NF-B signaling pathway by ND02 is implicated in its
molecular regulation of I/R-triggered inflammatory reac-
tions, because western blot analysis (Figure 4) verified
that phosphorylated IB-a and NF-B are alleviated,
but phosphorylated Akt is increased. Therefore, we
believe that the protective effects of ND02 could be due,
in large part, to suppression of inflammatory cascades
through an Akt-dependent NF-B signaling pathway.
In summary, the results of the current study suggest
that ND02 exhibits significant neuroprotective effects
during cerebral I/R injury, including attenuation of BBB
breakdown, decreased infarct volume, alleviated cerebral
damage, and reduced phosphorylated IB-a and NF-B
proteins in ischemic brain tissue. These effects of ND02
correlate with inhibition of the inflammatory response.
Moreover, unpublished results from our pharmacoki-
netic laboratory suggest that ND02 might penetrate the
blood-brain barrier. These findings point to a therapeu-
tic potential for ND02 as a useful anti-inflammatory
lead compound in early cerebral I/R injury.
Abbreviations
ND02: 6-O-acetyl shanzhiside methyl ester; MCAO: middle cerebral artery
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